These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25341043)

  • 1. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
    Bullenkamp J; Raulf N; Ayaz B; Walczak H; Kulms D; Odell E; Thavaraj S; Tavassoli M
    Cell Death Dis; 2014 Oct; 5(10):e1489. PubMed ID: 25341043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest.
    Li C; Johnson DE
    Cell Cycle; 2013 Mar; 12(6):923-34. PubMed ID: 23421999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
    Seki N; Toh U; Sayers TJ; Fujii T; Miyagi M; Akagi Y; Kusukawa J; Kage M; Shirouzu K; Yamana H
    Mol Cancer Ther; 2010 Jun; 9(6):1842-51. PubMed ID: 20515944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10.
    Raulf N; El-Attar R; Kulms D; Lecis D; Delia D; Walczak H; Papenfuss K; Odell E; Tavassoli M
    Br J Cancer; 2014 Nov; 111(10):1955-64. PubMed ID: 25314064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
    Lecis D; Drago C; Manzoni L; Seneci P; Scolastico C; Mastrangelo E; Bolognesi M; Anichini A; Kashkar H; Walczak H; Delia D
    Br J Cancer; 2010 Jun; 102(12):1707-16. PubMed ID: 20461078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
    Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
    Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.
    Unterkircher T; Cristofanon S; Vellanki SH; Nonnenmacher L; Karpel-Massler G; Wirtz CR; Debatin KM; Fulda S
    Clin Cancer Res; 2011 Jun; 17(12):4019-30. PubMed ID: 21525171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.
    Voortman J; Resende TP; Abou El Hassan MA; Giaccone G; Kruyt FA
    Mol Cancer Ther; 2007 Jul; 6(7):2103-12. PubMed ID: 17620439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.
    Jane EP; Premkumar DR; Pollack IF
    Mol Cancer Ther; 2011 Jan; 10(1):198-208. PubMed ID: 21220502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
    Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
    Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
    Ndozangue-Touriguine O; Sebbagh M; Mérino D; Micheau O; Bertoglio J; Bréard J
    Oncogene; 2008 Oct; 27(46):6012-22. PubMed ID: 18560353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
    Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
    Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
    Zhu H; Guo W; Zhang L; Wu S; Teraishi F; Davis JJ; Dong F; Fang B
    Cancer Biol Ther; 2005 Jul; 4(7):781-6. PubMed ID: 16082182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria.
    Nagy K; Székely-Szüts K; Izeradjene K; Douglas L; Tillman M; Barti-Juhász H; Dominici M; Spano C; Luca Cervo G; Conte P; Houghton JA; Mihalik R; Kopper L; Peták I
    Pathol Oncol Res; 2006; 12(3):133-42. PubMed ID: 16998592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV
    Xiao R; An Y; Ye W; Derakhshan A; Cheng H; Yang X; Allen C; Chen Z; Schmitt NC; Van Waes C
    Clin Cancer Res; 2019 Nov; 25(21):6463-6474. PubMed ID: 31266830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.
    Fulda S
    Oncotarget; 2011 May; 2(5):418-21. PubMed ID: 21789791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL.
    Liu FT; Agrawal SG; Gribben JG; Ye H; Du MQ; Newland AC; Jia L
    Blood; 2008 Mar; 111(5):2797-805. PubMed ID: 18160669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
    Shanker A; Brooks AD; Tristan CA; Wine JW; Elliott PJ; Yagita H; Takeda K; Smyth MJ; Murphy WJ; Sayers TJ
    J Natl Cancer Inst; 2008 May; 100(9):649-62. PubMed ID: 18445820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
    Ehrenschwender M; Bittner S; Seibold K; Wajant H
    Cell Death Dis; 2014 Dec; 5(12):e1570. PubMed ID: 25501831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.